Clinical Trial Update: Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Symbicort TURBUHALER 160/4.5 µg BID and Pulmicort TURBUHALER 200 µg BID plus Theolong Tablet 200 mg BID in J…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Pulmicort TURBUHALER 200 µg Twice Daily (budesonide)
• Symbicort TURBUHALER 160/4.5 µg Twice Daily (budesonide/formoterol)
• Theolong Tablet 200 mg Twice Daily (theophylline)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED